Do not settle for an email blasting service or a newswire overloaded with financial statements. Standard Newswire gets your news into the hands of working journalists, broadcast hosts, and news producers.
Find out how you can start using Standard Newswire to
Sign Up to Receive Press Releases:
Standard Newswire™ LLC
209 W. 29th Street, Suite 6202
New York, NY 10001, USA.
(212) 290-1585
Contact: Gary Stephenson. Johns Hopkins Medicine Media Relations and Public Affairs, 410-955-5384, gstephenson@jhmi.edu
Results of the study will be presented at a Late-Breaking Emerging Technologies and Innovations session on Sunday, March 25, at 2:50 p.m. at the
Using microcapsules, dubbed XCaps, that are visible using X-ray imaging techniques, the researchers were able to track the delivery, survival, and function of donor stem cells used to treat cardiovascular disease in rabbits
"In acute ischemia, you don't have the luxury of taking stem cells from the body and waiting two to three weeks to culture and expand them in the laboratory," says Dara L. Kraitchman, V.M.D., Ph.D., an associate professor of radiology at The Johns Hopkins University School of Medicine in Baltimore. "Ideally, we'd like to be able to take donor cells off the shelf, make them x-ray visible, protect them from the immune system, and deliver them precisely where we want them to be."
The researchers created the XCaps by coating donor stem cells with layers of alginate, a compound that provokes little immune response; barium, a contrast agent that makes the microcapsule X-ray visible; and poly-L-lysine, which holds the microcapsule together. The outer coating is made up of another layer of alginate.
The researchers replicated the effects of severe peripheral arterial disease in 13 female rabbits by inserting a platinum coil in the artery supplying blood to the hind limbs of the animals. One day later, the female rabbits were randomly assigned to receive an injection of XCaps created from the with stem cells of male rabbits, XCaps without stem cells, stem cells alone, or a sham injection. XCaps were visible on X-ray both immediately after injection and at two weeks, allowing the researchers to monitor the delivery and disposition of the XCaps.
"The nice thing about XCaps is that you can see each individual capsule very clearly on x-ray," says Dr. Kenyatta Cosby, a postdoctoral fellow at Johns Hopkins. "We also observed no accumulation of fibrous material around the capsules, which suggests a minimal immune response."
"Since XCaps can be made using FDA-approved clinical-grade compounds, they represent the first potentially biocompatible therapy that will enable X-ray visualization of stem cells to assist in targeting cellular therapeutics," Kraitchman says.
Other members of the
